A Phase I Study of Lintuzumab-Ac225 in People with Persistent Multiple Myeloma


Full Title

A Phase I Study of Lintuzumab-Ac225 in Patients with Refractory Multiple Myeloma


The purpose of this study is to find the highest dose of the investigational drug lintuzumab-Ac225 that can be given safely in patients with multiple myeloma that persists despite three or more prior treatments.

Lintuzumab-Ac225 is a type of radioimmunotherapy. It consists of an antibody, anti-CD33, that is chemically linked to a radioactive isotope. Lintuzumab-Ac225 binds to CD33 proteins in some cancerous cells in multiple myeloma. The isotope delivers cancer cell-killing radiation to the bone marrow and sometimes the spleen and liver, where most myeloma cells are present. Lintuzumab-Ac225 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has persisted despite three or more previous treatments.
  • Patients must have multiple myeloma containing the CD33 protein.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Sergio Giralt at 212-639-3859.